Webinar

Strategies for Optimizing Weight Health in Patients Coming off GLP-1 Agonists

Speakers

Edward Walker, PhD

Monique Class, MS, APRN-BC, IFMCP

26 minutes

Sign up for Academy to watch

Gain access to evolving research into evidence-based education that supports streamlined whole person care.

Create account

About this webinar

Amarasate®, a patented specific hop extract, has been clinically shown to significantly increase the production of endogenous glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK) by six-fold over baseline, and peptide YY (PYY) by four-fold over baseline. Backed by three published human clinical studies, Amarasate® reduces average calorie intake by 18%, hunger by 30%, and cravings by 40%. 

Discover the 15 years of science behind Amarasate® and its use in weight health programs to help patients manage rebound weight gain or in conjunction with low-dosing GLP-1 agonists.

Key takeaways

  • The history of bitter compound use for satiety
  • The discovery of Amarasate® from over 1,000 alternatives
  • A summary of the three human clinicals
  • Clinical usage and integration into patient care